文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

健康沟通与慢性高碳酸血症性呼吸衰竭患者无创通气依从性:一项随机临床试验

Health Communication and Adherence to Noninvasive Ventilation in Chronic Hypercapnic Respiratory Failure: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-12-02
一句话结论6周信息-动机-行为技能干预(IMB-NIV项目)可改善慢性高碳酸血症性呼吸衰竭患者12个月无创通气依从性(61.3% vs 27.4%)。

这项多中心、评估者盲法随机临床试验于2022年1月至2023年3月在香港2家区域医院的呼吸科门诊纳入124例对居家无创通气不依从的慢性高碳酸血症性呼吸衰竭患者。6周IMB-NIV项目采用面对面与远程医疗混合方式,提供知识、技能、积极态度和社会动机。12个月时IMB-NIV组依从率61.3% vs 常规护理组27.4%(OR 2.78,95%CI 1.69-4.55),每日无创通气使用小时数增加更多(B=2.37,95%CI 1.44-3.31),睡眠质量和健康相关生活质量改善更显著,急诊就诊率更低(IRR 0.47,95%CI 0.26-0.84),首次急诊就诊时间更长(HR 0.51,95%CI 0.28-0.95)。静脉HCO3-水平和住院次数无显著治疗效应。

要点

  • 12个月时IMB-NIV组无创通气依从率61.3% vs 常规护理组27.4%(OR 2.78,95%CI 1.69-4.55)。
  • IMB-NIV组每日无创通气使用小时数较常规护理组增加更多(B=2.37,95%CI 1.44-3.31)。
  • IMB-NIV组急诊就诊发生率更低(IRR 0.47,95%CI 0.26-0.84),首次急诊就诊时间更长(HR 0.51,95%CI 0.28-0.95)。
  • IMB-NIV组12个月睡眠质量(B=-3.63,95%CI -5.14至-2.12)和健康相关生活质量(β=14.84,95%CI 9.18-20.49)改善更显著。
  • 静脉HCO3-水平和住院次数无显著治疗效应。

适用人群与场景

  • 香港2家区域医院呼吸科门诊的慢性高碳酸血症性呼吸衰竭患者,且对处方居家无创通气不依从。
  • 年龄均值73.7岁(SD 7.2),女性67例(54.0%)。

处置流程与药物剂量

  • IMB-NIV项目为期6周,采用面对面与远程医疗混合方式,向患者提供知识、技能、积极态度和社会动机以增强无创通气依从性。

研究设计与关键结果

  • 多中心、评估者盲法随机临床试验,2022年1月至2023年3月在香港2家区域医院呼吸科门诊纳入124例对居家无创通气不依从的慢性高碳酸血症性呼吸衰竭患者,IMB-NIV组62例 vs 常规护理组62例。
  • 主要终点:12个月时IMB-NIV组无创通气依从率61.3% vs 常规护理组27.4%(OR 2.78,95%CI 1.69-4.55),IMB-NIV组每日无创通气使用小时数增加更多(B=2.37,95%CI 1.44-3.31)。
  • 12个月时IMB-NIV组睡眠质量改善更显著(B=-3.63,95%CI -5.14至-2.12),健康相关生活质量改善更显著(β=14.84,95%CI 9.18-20.49)。
  • IMB-NIV组急诊就诊发生率更低(IRR 0.47,95%CI 0.26-0.84),首次急诊就诊时间更长(HR 0.51,95%CI 0.28-0.95)。
  • 静脉HCO3-水平和住院次数无显著治疗效应。

证据类型、等级与局限

  • 证据类型:多中心、评估者盲法随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,IMB-NIV项目为改善慢性高碳酸血症性呼吸衰竭患者无创通气依从性提供了有前景的行为学方法。
  • 作者认为,该项目对睡眠质量、健康相关生活质量和急诊就诊的持续积极效应,凸显其优化无创通气治疗获益的潜力。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Domiciliary noninvasive ventilation (NIV) is a standard treatment for improving health outcomes among patients with chronic hypercapnic respiratory failure (CHRF). However, poor adherence substantially limits its therapeutic effectiveness.

OBJECTIVE: To determine the effect of an information-motivation-behavioral (IMB) skills-based intervention (IMB-NIV program) on NIV adherence, patient-reported health outcomes, and health service use among patients with CHRF.

DESIGN, SETTING, AND PARTICIPANTS: This multisite, assessor-blinded, randomized clinical trial was conducted from January 2022 to March 2023 at respiratory clinics of 2 regional hospitals in Hong Kong among patients with CHRF who had been nonadherent to prescribed domiciliary NIV.

INTERVENTIONS: The 6-week IMB-NIV program used a hybrid approach, combining in-person and telecare sessions, to provide patients with knowledge, skills, a positive attitude, and social motivation to enhance NIV adherence.

MAIN OUTCOMES AND MEASURES: The primary outcome was NIV adherence data retrieved from the NIV machine. Secondary outcomes included the Pittsburgh Sleep Quality Index, Chinese Severe Respiratory Insufficiency questionnaire, venous bicarbonate (HCO3-) level, emergency department (ED) and hospital admissions, and mortality measured at baseline, program completion, and 3, 6, and 12 months.

RESULTS: Of the 124 participants (mean [SD] age, 73.7 [7.2] years; 67 [54.0%] female), the 62 patients in the IMB-NIV group were more likely to adhere to NIV compared with the 62 patients in the usual care group at 12 months (61.3% vs 27.4%; odds ratio, 2.78; 95% CI, 1.69 to 4.55), with a greater increase noted in daily NIV use in hours at that time (B = 2.37; 95% CI, 1.44 to 3.31). A generalized estimating equation indicated significantly greater improvements in sleep quality (B = -3.63; 95% CI, -5.14 to -2.12) and health-related quality of life (β = 14.84; 95% CI, 9.18 to 20.49) at 12 months in the IMB-NIV group. The IMB-NIV group had significantly lower ED admissions (incidence rate ratio, 0.47; 95% CI, 0.26 to 0.84) and a longer time to the first ED visit (hazard ratio, 0.51; 95% CI, 0.28 to 0.95). No significant treatment effect was observed on venous HCO3- levels or hospital admissions.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the IMB-NIV program offered a promising behavioral approach to improve NIV adherence in patients with CHRF. Its sustained positive effects on sleep quality, health-related quality of life, and ED admissions highlight its potential to optimize the therapeutic benefits of NIV.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05008211.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Yu DSF, Li PW, Lau JC, et al. Health Communication and Adherence to Noninvasive Ventilation in Chronic Hypercapnic Respiratory Failure: A Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39724376. doi:10.1001/jamanetworkopen.2024.51614

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。